Free Trial

TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Rated "Moderate Buy" by Sell-Side Analysts

TG Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $63.00.

Several brokerages have recently weighed in on TGTX. JPMorgan Chase & Co. raised their target price on TG Therapeutics from $65.00 to $72.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Weiss Ratings upgraded TG Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Wednesday, November 4th. B. Riley Financial upped their price target on TG Therapeutics from $55.00 to $86.00 and gave the company a "buy" rating in a report on Monday, July 27th. Zacks Research upgraded shares of TG Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, November 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $78.00 price target on shares of TG Therapeutics in a research note on Tuesday, September 1st.

Read Our Latest Research Report on TG Therapeutics

Insider Buying and Selling at TG Therapeutics

In other news, Director Laurence Charney sold 5,000 shares of the company's stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total value of $274,800.00. Following the completion of the transaction, the director owned 168,640 shares in the company, valued at approximately $9,268,454.40. This represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 8.87% of the company's stock.

Institutional Investors Weigh In On TG Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of TG Therapeutics in the second quarter valued at approximately $1,211,429,000. First Trust Advisors LP grew its position in shares of TG Therapeutics by 1,053.0% during the third quarter. First Trust Advisors LP now owns 1,921,540 shares of the biopharmaceutical company's stock worth $107,184,000 after acquiring an additional 1,754,886 shares during the last quarter. Bank of America Corp DE grew its position in shares of TG Therapeutics by 71.7% during the first quarter. Bank of America Corp DE now owns 1,461,302 shares of the biopharmaceutical company's stock worth $48,544,000 after acquiring an additional 610,195 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of TG Therapeutics by 129.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company's stock valued at $36,029,000 after acquiring an additional 612,068 shares during the period. Finally, Public Sector Pension Investment Board increased its holdings in shares of TG Therapeutics by 115.0% in the 3rd quarter. Public Sector Pension Investment Board now owns 973,454 shares of the biopharmaceutical company's stock valued at $52,635,000 after acquiring an additional 520,637 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $64.51 on Monday. The stock has a market cap of $9.75 billion, a PE ratio of 97.74, a P/E/G ratio of 5.08 and a beta of 1.89. The company has a debt-to-equity ratio of 1.30, a current ratio of 4.50 and a quick ratio of 3.75. The stock's fifty day moving average is $56.69 and its two-hundred day moving average is $45.33. TG Therapeutics has a 1-year low of $26.76 and a 1-year high of $68.03.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.01). TG Therapeutics had a return on equity of 18.82% and a net margin of 11.81%. The business had revenue of $259.94 million for the quarter, compared to analyst estimates of $245.47 million. During the same period in the prior year, the company posted $2.43 earnings per share. The company's revenue was up 60.8% compared to the same quarter last year. On average, sell-side analysts expect that TG Therapeutics will post 1.10 EPS for the current fiscal year.

About TG Therapeutics

(Get Free Report)

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company's marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Further Reading

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in TG Therapeutics Right Now?

Before you consider TG Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.

While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines